[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610453":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":37,"responsibleParty":80,"collaborators":82,"id":85,"slug":18,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":18,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":18,"enrollmentInfo":93,"targetDuration":18,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":18,"overallStatus":102,"whyStopped":18,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"University of Minnesota","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"BPaLMZ Regimen","EXPERIMENTAL","bedaquiline, pretomanid, linezolid, moxifloxacin, and pyrazinamide (BPaLMZ)",[13],"Drug: BPaLMZ Regimen",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard of Care Regimen","NO_INTERVENTION","rifampicin, isoniazid, pyrazinamide, ethambutol (RHZE) therapy",null,[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":18},"DRUG","bedaquiline, pretomanid, linezolid, moxifloxacin, and pyrazinamide",[9],[25],{"name":26,"affiliation":5,"role":27},"David Boulware, MD","PRINCIPAL_INVESTIGATOR",[29,33],{"name":26,"role":30,"phone":31,"phoneExt":18,"email":32},"CONTACT","612-624-9996","coat.trial@gmail.com",{"name":34,"role":30,"phone":35,"phoneExt":18,"email":36},"Darlisha Williams, MPH","612-624-0469","will1223@umn.edu",[38,53,67],{"facility":5,"status":18,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Minneapolis","Minnesota","55455","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-93.26384,44.97997,{"lat":48,"lon":47},[51],{"name":26,"role":30,"phone":31,"phoneExt":18,"email":52},"Coat.trial@gmail.com",{"facility":54,"status":18,"city":55,"state":18,"zip":18,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Infectious Diseases Institute","Kampala","Uganda","UG",{"type":45,"coordinates":59},[60,61],32.58219,0.31628,{"lat":61,"lon":60},[64],{"name":65,"role":30,"phone":18,"phoneExt":18,"email":66},"David Meya, MBChB, MMed, PhD","david.meya@idi.co.ug",{"facility":68,"status":18,"city":69,"state":18,"zip":18,"country":56,"countryCode":57,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Mbarara University of Science and Technology","Mbarara",{"type":45,"coordinates":71},[72,73],30.64851,-0.60467,{"lat":73,"lon":72},[76],{"name":77,"role":30,"phone":78,"phoneExt":18,"email":79},"Conrad Muzoora","256772547175","conradmuzoora@gmail.com",{"type":81,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[83],{"name":54,"class":84},"UNKNOWN","100610453",false,"NCT07227779","B-PaLMZ for TB Meningitis","A PHASE 2 NOVEL ANTIMICROBIAL COMBINATION THERAPY TO TREAT TUBERCULOUS MENINGITIS","Inclusion Criteria:\n\n* First Episode definite or probable TBM with physician intent to treat\n* Age ≥18 years\n* Provision of Informed Consent by participant or surrogate\n* Living with HIV\n* Weight \\> 35kg, estimate or measured\n\nExclusion Criteria:\n\n* Additional active and confirmed CNS infection\n* Known rifampicin-resistant TB\n* Allergy or contraindication to a study medicine\n* More than 5 doses of any TB therapy received within the previous 14 days\n* Presence of jaundice, known liver cirrhosis, elevated ALT or AST \\>3x ULN, or total bilirubin \\>2x ULN\n* Estimated Glomerular Filtration Rate \\\u003C30 ml\u002Fmin\u002F1.73m2\n* Significant cardiac comorbidity, heart failure, arrhythmia, or QTc \\>450 ms\n* Pregnancy or Breastfeeding\n* Cryptococcal antigen positivity in blood\n* Condition which makes participation not in the participant's best interest","ALL","18 Years",{"count":94,"type":95},240,"ESTIMATED","INTERVENTIONAL",[98],"PHASE2","This two-stage study will compare consented research participants with tuberculous meningitis receiving BPaLMZ to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE.",[101],"Tuberculous Meningitis","NOT_YET_RECRUITING","2026-06-17",{"date":105,"type":106},"2026-06-22","ACTUAL",{"date":108,"type":95},"2026-07-20",{"date":110,"type":95},"2030-08-31",{"name":5,"class":6},3]